Article

Are your beneficiary designations up to date?

There is never a bad time to revisit the beneficiary designations you have made over the years.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Sandip Prasad, MD, on key data from pivotal ENVISION trial of mitomycin intravesical solution
Sandip Prasad, MD, on key data from pivotal ENVISION trial of mitomycin intravesical solution
Future patient profiles for TARA-002
Future patient profiles for TARA-002
Safety and tolerability of TARA-002
Safety and tolerability of TARA-002
Related Content
3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
August 19th 2025

PSMA PET/CT prior to salvage radiotherapy may improve overall survival

Hannah Clarke
Introducing First Assist: GU Oncology Unpacked, with Taylor Goodstein, MD!
August 19th 2025

Introducing First Assist: GU Oncology Unpacked, with Taylor Goodstein, MD!

Taylor Goodstein, MD
FDA grants fast track designation to HLD-0915 in mCRPC
August 19th 2025

FDA grants fast track designation to HLD-0915 in mCRPC

Hannah Clarke
Pearls & Perspectives: Bringing the Magic Back to Medicine, with David Canes, MD
August 19th 2025

Pearls & Perspectives: Bringing the Magic Back to Medicine, with David Canes, MD

Amy M. Pearlman, MD
FDA grants de novo authorization to ArteraAI Prostate
August 19th 2025

FDA grants de novo authorization to ArteraAI Prostate

Hannah Clarke Benjamin P. Saylor
FDA grants priority review to gepotidacin for uncomplicated urogenital gonorrhea
August 19th 2025

FDA grants priority review to gepotidacin for uncomplicated urogenital gonorrhea

Hannah Clarke
© 2025 MJH Life Sciences

All rights reserved.